Sign in
Taking people in United StatesPhase 2/3

Tests RP2 with nivolumab against ipilimumab with nivolumab in uveal melanoma

Compares RP2 plus nivolumab with ipilimumab plus nivolumab in adults with metastatic uveal melanoma.

Key facts

Who runs it
Replimune, Inc.
Where
Atlanta, Aurora, Boston, Chicago, Columbus, Dallas, Durham, Englewood, Germantown, Houston, Iowa City, Jacksonville, Knoxville, La Jolla, Los Angeles, Madison, Miami, Nashville, New York, Palo Alto, Philadelphia, Pittsburgh, Rochester, Scottsdale, Seattle, and Washington D.C., United StatesSee the 29 sitesAlso in 7 other countries, 14 sites
Registry title
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Status
Recruiting
Phase
Phase 2/3
People taking part
280 people, planned
Started
17 Dec 2024
Expected to end
Oct 2031
Type of study
Interventional, 2 groups
Treatments tested
  • RP2
  • Ipilimumab
  • Nivolumab
Record updated
2 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with uveal melanoma that has spread and cannot be removed by surgery, and who have never had immune checkpoint inhibitor treatment.

Age
18 years or older
Sex
All sexes can join
Disease stage
Confirmed metastatic uveal melanoma that cannot be removed by surgery. At least 1 measurable tumor of 1 cm (0.4 in) or more across (1.5 cm or more in the shortest axis for a lymph node) that can be injected. ECOG performance status 0 or 1. LDH up to 2 times the upper limit of normal. Life expectancy over 6 months.
Earlier treatment
No immune checkpoint inhibitor since the uveal melanoma was first diagnosed. No earlier oncolytic virus treatment.

Main reasons for not taking part

  • Any earlier treatment with an immune checkpoint inhibitor
  • Melanoma in the central nervous system, including carcinomatous meningitis
  • Known hepatitis B or C, HIV, or other uncontrolled infection
  • Active herpes infection, or earlier complications of HSV-1 infection
  • Active autoimmune disease that needs treatment with medicines that act on the whole body

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Patients who are 18 years of age or older at the time of signed informed consent
  • Patients with confirmed diagnosis of metastatic Uveal melanoma not amenable to surgical resection
  • Has at least 1 measurable and injectable tumor of ≥ 1 cm in longest diameter (≥ 1.5 cm in the shortest axis for a lymph node [LN]) that is amenable to serial RP2 injections
  • Must be willing to provide tumor biopsy samples
  • LDH ≤ 2 × upper limit of normal (ULN)
  • Has adequate hematologic, hepatic and renal function
  • Prothrombin time (PT) ≤ 1.5 × ULN (or international normalization ratio [INR] ≤ 1.3) and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
  • Life expectancy of > 6 months as estimated by the Investigator

Who cannot take part

  • Any exposure to immune checkpoint inhibitor (ICIs) since the time of first being diagnosed with uveal melanoma
  • Current active significant herpetic infections or prior complications of HSV-1 infection
  • Major surgery ≤ 2 weeks prior to the first dose of study intervention
  • Prior treatment with an oncolytic virus
  • Systemic anticancer therapy or prior radiotherapy within 2 weeks of the first dose
  • Has received Investigation agent within 4 weeks or 5 half-lives (whichever longer) prior to the first dose
  • Conditions requiring treatment with immunosuppressive doses (> 10 mg per day of prednisone or equivalent) of systemic corticosteroids other than for corticosteroid replacement therapy within 14 days after enrollment; Additional inclusion/ exclusion criteria are outlined in the study protocol
  • Known acute or chronic Hepatitis B or C infection or human immunodeficiency virus (HIV) infection or any other uncontrolled infection
  • Any bleeding, thrombotic and/or other event that places the patient at an unacceptable risk of complications of intratumoral therapy
  • Active, known, or suspected autoimmune disease requiring systemic treatment
  • Any central nervous system (CNS) involvement of melanoma, including carcinomatous meningitis
  • Requires intermittent or chronic use of systemic (oral or IV) antivirals with known antiherpetic activity (eg, acyclovir)

Where in United States

Also in 7 other countries, 14 sites

  • Emory Winship Cancer InstituteAtlanta, United StatesContact: Michael Lowe, MDTaking people
  • University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)Aurora, United StatesContact: Sapna Pradyuman Patel, MDTaking people
  • Massachusetts General HospitalBoston, United StatesContact: Kamaneh Montazeri, MDTaking people
  • Northwestern Memorial HospitalChicago, United StatesContact: Sunandana Chandra, MD, MSTaking people
  • University of Chicago Medical CenterChicago, United StatesContact: Daniel Olson, MDTaking people
  • The Ohio State UniversityColumbus, United StatesContact: Richard Wu, MD, PhDTaking people
  • UT Southwestern Medical CenterDallas, United StatesContact: Sanjay Chandrasekaran, MDTaking people
  • Duke University Medical CenterDurham, United StatesContact: April Salama, MDTaking people
  • The Melanoma & Skin Cancer InstituteEnglewood, United StatesContact: Ryan Weight, DO, MSTaking people
  • The West Clinic, PLLC dba West Cancer CenterGermantown, United StatesContact: Arnel M. Pallera, MDTaking people
  • The University of Texas MD Anderson Cancer CenterHouston, United StatesContact: Alexandra Ikeguchi, MDTaking people
  • University of IowaIowa City, United StatesContact: Asad Javed, MDTaking people
  • Mayo Clinic- Jacksonville, FLJacksonville, United StatesContact: Roxana S. Dronca, MDTaking people
  • University of Tennessee Medical CenterKnoxville, United StatesContact: Timothy Panella, MDTaking people
  • UC San Diego Moores Cancer CenterLa Jolla, United StatesContact: Gregory Daniels, MDTaking people
  • The Angeles Clinic and Research InstituteLos Angeles, United StatesContact: Inderjit Mehmi, MDTaking people
  • University of California, Los AngelesLos Angeles, United StatesContact: Bartosz Chmielowski, MDTaking people
  • University of Wisconsin Carbone Cancer Center - University HospitalMadison, United StatesContact: Vincent Ma, MDTaking people
  • Sylvester Comprehensive Cancer Center*Miami, United StatesContact: Leonel Fernando Hernandez Aya, MDTaking people
  • Sarah Cannon Research InstituteNashville, United StatesContact: Meredith Ann McKean, MD, MPHTaking people
  • Vanderbilt Ingram Cancer Center (Henry-Joyce Cancer Clinic)Nashville, United StatesContact: Douglas B. Johnson, MDTaking people
  • Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Alexander Shoushtari, MDTaking people
  • Stanford Cancer InstitutePalo Alto, United StatesContact: Allison Betof Warner, MDTaking people
  • Thomas Jefferson UniversityPhiladelphia, United StatesContact: Marlana Orloff, MDTaking people
  • UPMC Hillman Cancer CenterPittsburgh, United StatesContact: Diwakar Davar, MDTaking people
  • Mayo Clinic - RochesterRochester, United StatesContact: Arkadiusz Z. Dudek, MDTaking people
  • HonorHealth Research InsisuteScottsdale, United StatesContact: Justin Moser, MDTaking people
  • Fred Hutchinson Cancer CenterSeattle, United StatesContact: Natalie Miller, MD, PhDTaking people
  • Georgetown University Medical CenterWashington D.C., United StatesContact: Suthee Rapisuwon, MDTaking people

About the trial

What the trial wants to find out

The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.

The 2 groups in the trial

  • Test Arm: RP2 + nivolumabTreatment being tested

    RP2 (Oncolytic virus) and Nivolumab (programmed death receptor-1 (PD-1) inhibitor)

    Treatment: RP2 and Nivolumab

  • Control Arm (Active Comparator): ipilimumab + nivolumabTreatment being tested

    Immune Checkpoint inhibitor combination

    Treatment: Ipilimumab and Nivolumab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab Versus Ipilimumab in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Plain-language title
Tests RP2 with nivolumab against ipilimumab with nivolumab in uveal melanomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
2 April 2026